Pluristem Therapeutics Statistics Share Statistics Pluristem Therapeutics has 40.85M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 40.85M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 31.29M Failed to Deliver (FTD) Shares n/a FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 336.69K, so 0% of the outstanding
shares have been sold short.
Short Interest 336.69K Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 3.25
Valuation Ratios The PE ratio is -2.23 and the forward
PE ratio is null.
Pluristem Therapeutics's PEG ratio is
-0.21.
PE Ratio -2.23 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 1.95 P/FCF Ratio -3.56 PEG Ratio -0.21
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Pluristem Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 5.85,
with a Debt / Equity ratio of 0.43.
Current Ratio 5.85 Quick Ratio 5.85 Debt / Equity 0.43 Debt / EBITDA -0.51 Debt / FCF -0.79 Interest Coverage -649.01
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-325.92K Employee Count 153 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by null% in the
last 52 weeks. The beta is 1.91, so Pluristem Therapeutics's
price volatility has been higher than the market average.
Beta 1.91 52-Week Price Change n/a 50-Day Moving Average 1.27 200-Day Moving Average n/a Relative Strength Index (RSI) 32.85 Average Volume (20 Days) n/a
Income Statement
Revenue n/a Gross Profit n/a Operating Income -50.62M Net Income -49.87M EBITDA -48.42M EBIT -49.79M Earnings Per Share (EPS) -1.77
Full Income Statement Balance Sheet The company has 31.24M in cash and 24.58M in
debt, giving a net cash position of 6.66M.
Cash & Cash Equivalents 31.24M Total Debt 24.58M Net Cash 6.66M Retained Earnings -330.02M Total Assets 79.13M Working Capital 56.49M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -30.91M
and capital expenditures -373K, giving a free cash flow of -31.28M.
Operating Cash Flow -30.91M Capital Expenditures -373K Free Cash Flow -31.28M FCF Per Share -1.11
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields PSTI does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for PSTI.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jul 25, 2019. It was a
backward
split with a ratio of 1:10.
Last Split Date Jul 25, 2019 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -6.86 Piotroski F-Score 4
